Urgences
Traitements
Infos médecins
Centre de recherche
Faire un don
Liens |
|
 |
|
|
|
| Home < Centre de recherche < Publications 2010 < Publications 2005 |     |
| Info.onco@chuv.ch |
2005 |
||
| 1: | Aapro M.S., Leyvraz S. | |
| L'indépendance de la recherche clinique survivra-t-elle ?
Rev. Med. Suisse 20, 1323-1324, 2005. |
||
| 2: | Antonescu C, Bischof Delaloye A, Kosinski M, Monnin P, Schaffland AO, Ketterer N, Grannavel C, Kovacsovics T, Verdun FR, Buchegger F. | |
| Repeated injections of (131)I-rituximab show patient-specific stable biodistribution and tissue kinetics
Eur J Nucl Med Mol Imaging, 32:943-51, 2005 |
||
| 3: | Appay V, Reynard S, Voelter V, Romero P, Speiser DE, Leyvraz S. | |
| Immuno-monitoring of CD8+ T cells in whole blood versus PBMC samples
J Immunol Methods. Feb 20;309(1-2):192-9, 2006. |
||
| 4: | Azria D, Magne N, Zouhair A, Castadot P, Culine S, Ychou M, Stupp R, van Houtte P, Dubois JB, Ozsahin M. | |
| Radiation recall. A well recognized but neglected phenomenon.
Cancer Treat Rev 31:555-570, 2005 (Epub 13 Sep) |
||
| 5: | Bauer J, S. Leyvraz | |
| Les liaisons dangereuses : interactions entre médecins de premier recours et oncologues médicaux.
Rev. Med. Suisse 20, 1356-1358, 2005 |
||
| 6: | Broillet A, J. Hantson, C. Ruegg, T. Messager, and M. Schneider | |
| Assessment of microvascular perfusion changes in a rat breast tumor model using SonoVue™ to monitor the effects of different anti-angiogenic therapies
Acad. Radiol., 12 Suppl 1:S28-33, 2005 |
||
| 7: | Calzascia T, W. Besson, F. Masson, E. Contasso, R. Wilmotte, A. Aurrand-Lions, C. Rüegg, P-Y. Dietrich and P. Walker | |
| Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs.
Immunity, 22:175-84., 2005 |
||
| 8: | Eggermont AM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W, Punt CJ, Delauney M, Sales F, Groenewegen G, Ruiter DJ, Jagiello I, Stoitchkov K, Keilholz U, Lienard D; EORTC Melanoma Group. | |
| Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Department of Surgical Oncology, Erasmus University Medical Centre-Daniel den Hoed Cancer Centre, 3008 AE Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
Lancet. Oct 1;366(9492):1189-96., 2005 |
||
| 9: | Filges I, Zaman K, Michielin O, Vulliemoz D, Perey L, Stupp R | |
| Present chemoprevention and future vision
Rev Med Suisse;1:1343-6, 1349, 2005 |
||
| 10: | Foletti A, G-C. Alghisi, L. Ponsonnet and C. Rüegg. | |
| Isolated integrin β1 and β3 subunit cytoplasmic domains require membrane anchorage to recruit to adhesion complexes but cannot discriminate between β1-fibrillar adhesions and β3+-focal adhesions Thromb
Haemost., 94: 155-166, 2005 |
||
| 11: | George AC, M. Ozsahin, R. Janzer, S. Agassis, R. Meuli, A.S. Baur, V. Frossard, S. Leyvraz, N. Ketterer | |
| Primary intracranial dural lymphoma of mucosa-associated lymphoid tissue (MALT) type : report of one case and review of the literature
Bull. Cancer 92 : E51-6, 2005 |
||
| 12: | Ghielmini M, Rufibach k, Salles G, Leoncini-Franscini L, Leger-Falandry C, Cogliatti S, Fey MF, Martinelli G, Stahel R, Lohri A, Ketterer N, Wernli M, Cerny T, Schmitz SF | |
| Single agent rituximab in patients with follicular or mantle cell lymphoma
Ann Oncol.;16:1675-82, 2005 |
||
| 13: | Ghielmini M, Schmitz SF, Cogliatti S, Bertoni F, Waltzer U, Fey MF, Betticher DC, Schefer H, Pichert G, Stahel R, Ketterer N, Bargetzi M, Cerny T. | |
| Effect of Single-Agent Rituximab Given at the Standard Schedule or As Prolonged Treatment in Patients With Mantle Cell Lymphoma: A Study of the Swiss Group for Clinical Cancer Research (SAKK)
J Clin Oncol.;23:705-11, 2005 |
||
| 14: | Goerres GW, R. Stupp, G. Barghouth, T.F. Hany, B. Pestalozzi, E. Dizendorf, P. Schnyder, F. Luthi, G.K. von Schulthess, S. Leyvraz | |
| The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumors (GIST) : long-term outcome of patients treated with Imatinib mesylate.
Eur. J. Nucl. Med. Mol. Imaging. 32(2) : 153-162, 2005. |
||
| 15: | Hasmim M, G. Vassalli, L. Ponsonnet, G. Vassalli, J. Bamat, C. Bieler, J. Paroz, D. Oguey, and C. Rüegg | |
| Endothelial cell death induced by expression of isolated integrin β1 subunit cytoplasmic domain in vitro and in vivo is secondary to cell detachment Thromb.
Haemost., 94: 1060-1070, 2005 |
||
| 16: | Hegi, ME; Diserens, AC; Gorlia, T; Hamou, MF; de Tribolet, N; Weller, M ; Kros, JM; Hainfellner, JA; Mason, WP; Mariani, L; Bromberg, JEC; Hau, P; Mirimanoff, RO; Cairncross, JG; Janzer, RC; Stupp, R: | |
| MGMT gene silencing and Benefit from Temozolomide chemotherapy and MGMT gene silencing in Glioblastoma.
N Engl J Med 352:997-1003, 2005 |
||
| 17: | International Breast Cancer Study Group (IBCSG) (Lausanne : S. Levyraz) | |
| Timing of CMF chemotherapy in combination with Tamoxifen in postmenopausal women with breast cancer : role of endocrine responsiveness of the tumor.
Ann. Oncol. 16 : 716-725, 2005. |
||
| 18: | Keilholz U, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, Thomas J, Proebstle TM, Schmittel A, Schadendorf D, Velu T, Negrier S, Kleeberg U, Lehman F, Suciu S, Eggermont AM | |
| Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group
J Clin Oncol., Sep 20;23(27):6747-55., 2005 |
||
| 19: | Leimgruber A, Ostermann S, Yeon EJ, Buff E, Maeder PP, Stupp R, Meuli RA | |
| Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide trial.
Int J Radiat Oncol Biol Phys 64:869-875, 2006 |
||
| 20: | Leon X, Hitt R, Constenla M, Rocca A, Stupp R, Kovacs AF, Amelal N, Bessa EH, Bouhis J. | |
| A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to platinum-based chemotherapy.
Clin Oncol (R Coll Radiol) 17:418-24, 2005 |
||
| 21: | Leupin N, J. Bauer, F. Luthi, D. Liénard, D. Vuillemoz, S. Leyvraz | |
| Le dépistage du cancer.
Rev. Med. Suisse 20, 1328-1334, 2005 |
||
| 22: | Leyvraz S., Jelic S. | |
| ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of soft tissue sarcomas
Ann. Oncol. 16 : 169-170, 2005 |
||
| 23: | Monnier Y, J. Zaric and C. Rüegg | |
| Inhibition of Angiogenesis by Non-Steroidal Anti-Inflammatory Drugs: From the bench to the bedside and back.
Curr Drug Targets, 4, 33-40, 2005 |
||
| 24: | Montes M, N. Rufer, V. Appay, S. Reynard, M.J. Pittet, D.E. Speiser, P. Guillaume, J.C. Cerottini, P. Romero, S. Leyvraz | |
| Optimum in vitro expansion of human antigen-specific CD8+ T cells for adoptive transfer therapy
Clin Exp Immunol. 142 : 292-302, 2005 |
||
| 25: | Moreau P, Hullin C, Garban F, Yacoub-Agha I, Benboubker L, Attal M, Marit G, Fuzibet JG, Doyen C, Voillat L, Berthou C, Ketterer N, Casassus P, Monconduit M, Michallet M, Najman A, Sotto Jj, Bataille R, Harousseau JL. | |
| Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol
Blood Sep 6; 2005 |
||
| 26: | Pezzetta E, Stupp R, Zouhair A, Guillou L, Taffé P, von Briel C, Krueger T, Ris HB | |
| Comparison of neoadjuvant cisplatin-based chemotherapy versus radiochemotherapy followed by resection for stage III (N2) NSCLC
Europ J Cardiothorac Surg 27:1092-1098, 2005 |
||
| 27: | Rüegg C, M. Hasmim, F. Lejeune and G.C Alghisi | |
| Anti-angiogenic peptides and proteins: from experimental tools to clinical drugs Biochim Biophys Acta Rev on
Cancer, 2005 Oct 7 [Epub ahead of print], 2005 |
||
| 28: | Seium Y, Stupp R, Rusthaller T, Gervaz P, Mentha G, Philippe M, Allal A, Trembleau C, Bauer J et al | |
| Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study
Annals of Oncology 16 (5): 762-6, 2005 |
||
| 29: | Sessa C, De Braud F, Perotti A, Bauer J et al | |
| Trabectidin for women with ovarian carcinoma after treatment with platinum and taxanes fails
J Clin Oncol: 23(9): 1867-74, 2005 |
||
| 30: | Speiser, D.E., Liénard, D., Rufer, N., Rubio-Godoy, V., Rimoldi, D., Lejeune, F., Krieg, A.M., Cerottini, J.-C., Romero, P. | |
| Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA and CpG oligodeoxynucleotide 7909
J.Clin.Invest. 115:739-746, 2005 |
||
| 31: | Stupp R, Hegi ME, van den Bent MJ | |
| Optimal role of temozolomide in the treatment of malignant gliomas.
Curr Neurol Neurosci Rep 5:198-206, 2005 |
||
| 32: | Stupp, R; Mason, WP; van den Bent, MJ; Weller, M.; Fisher, B.; Taphoorn, M. J. B.; Belanger, K.; Brandes, A. A.; Cairncross, J. G.; Marosi, C; Bogdahn, U; Curschmann, J; Janzer, R. C.; Ludwin, SK; Gorlia, T.; Allgeier, A.; Lacombe, D.; Eisenhauer, E; Mirimanoff, R. O.; | |
| on behalf of European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor and Radiotherapy Groups and National Cancer Institute of Canada Clinical Trials Group (NCIC CTG).
N Engl J Med 352:987-996, 2005 |
||
| 33: | The Breast International Group (BIG) 1-988 Collaborative Group. (Lausanne : S. Leyvraz). | |
| A comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer
The New England Journal of Medicine, 353 ; 26 : 2747-2757, December 2005 |
||
| 34: | Villard V, O. Kalyuzhniy O. Riccio, S. Potekhin, T. N. Melnik, A.V. Kajava, C. Rüegg and G. Corradin | |
| Synthetic RGD-containing α-Helical Coiled Coil Peptides promote Integrin-Dependent Cell Adhesion.
J. Peptide Sci., Aug 15 [Epub ahead of print], 2005 |
||
| 35: | Voelter V, R.O. Mirimanoff, F. Stiefel, I. Rousselle, S. Leyvraz | |
| L'annonce d'une mauvaise nouvelle en oncologie
Rev. Med. Suisse 20, 1350-1353, 2005 |
||
| 36: | Wasserfallen JB, Ostermann S, Pica A, Mirimanoff RO, Leyvraz S, Villemure JG, Stupp R. | |
| Cost of temozolomide therapy and global care for recurrent malignant glioma followed until death.
Neuro-Oncology 7:189-195, 2005 |
||
| 37: | Zaman K, Driscoll R, Hahn D, Werffeli P, Goodman SL, Bauer J, Leyvraz S, Lejeune F, Stupp R, Ruegg C. | |
| Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy.
Int J Cancer 118: 755-764, 2006 (epub 19 Aug 2005) |
||
| 38: | Zaric J, and C. Rüegg. | |
| Integrin-mediated adhesion induces COX-2 activity by promoting COX-2 protein stability
J. Biol. Chem., 280: 1077-85, 2005 |
||
| 39: | Zimmermann M, Luthi, F, Zouhair A, Ketterer N, Kamel ME, Bischof-delaloye A | |
| PET contribution in oncology.
Rev Med Suisse.;1:1335-8, 1335-42, 2005 |
||
| 40: | van Baren N, Bonnet MC, Dreno B, Khammari A, Dorval T, Piperno-Neumann S, Lienard D, Speiser D, Marchand M, Brichard VG, Escudier B, Negrier S, Dietrich PY, Maraninchi D, Osanto S, Meyer RG, Ritter G, Moingeon P, Tartaglia J, van der Bruggen P, Coulie PG, Boon T | |
| Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T-cells.
J Clin Oncol. 2005 Dec 10;23(35):9008-21. Epub Aug. 2005 |
||
Dernière modification le
16.04.2009